Publicaciones científicas
-
Circulating GDF11 levels are decreased with age but are unchanged with obesity and type 2 diabetes
Añón-Hidalgo J (1), Catalán V (1,2,3), Rodríguez A (1,2,3), Ramírez B (1,2,3), Silva C (2,3,4), Galofré JC (4), Salvador J (2,4), Frühbeck G (1,2,3,4), Gómez-Ambrosi J (1,2,3).
(1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
(2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Pamplona, Spain.
(3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
(4) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.Aging 21 de MARZO de 2019
-
Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine
Grigorian Shamagian L (1,2), Madonna R (3,4), Taylor D (5), Climent AM (1,2), Prosper F (6), Bras-Rosario L (7), Bayes-Genis A (2,8), Ferdinandy P (9,10), Fernández-Avilés F (1,2), Izpisua Belmonte JC (11), Fuster V (2,12,13), Bolli R (14).
(1) From the Hospital Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Madrid, Spain (L.G.S., A.M.C., F.F.-A.).
(2) CIBERCV, ISCIII, Madrid, Spain (L.G.S., A.M.C., A.B.-G., F.F.-A., V.F.).
(3) Center of Aging Sciences and Translational Medicine (CESI-MeT), Institute of Cardiology, G. d'Annunzio University, Chieti, Italy (R.M.).
(4) Department of Internal Medicine, the University of Texas Health Science Center at Houston (R.M., ).
(5) Texas Heart Institute, Houston (D.T.).
(6) Clinica Universidad de Navarra, Pamplona, Spain (F.P.).
(7) Cardiology Department, Santa Maria University Hospital (CHLN), Lisbon Academic Medical Centre and Cardiovascular Centre of the University of Lisbon, Faculty of Medicine, Portugal (L.B.-R.).
(8) Hospital Germans Trias i Pujol, Badalona, Spain (A.B.-G.)
(9) Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary (P.F.).
(10) Pharmahungary Group, Szeged, Hungary (P.F.).
(11) Salk Institute for Biological Studies, La Jolla (J.C.I.B.).
(12) The Mount Sinai Hospital, New York, NY (V.F.).
(13) Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain (V.F.).
(14) University of Louisville (R.B.).Circulation Research 15 de MARZO de 2019
-
Cutis verticis gyrata primario no esencial pruriginoso
Tomás-Velázquez A (1), Moreno-Artero E (2), Abengózar M (3), Palacios-Álvarez I (2)
(1) Departamento de Dermatología Médico-Quirúrgica y Venereología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
(2) Departamento de Dermatología Médico-Quirúrgica y Venereología, Clínica Universidad de Navarra, Pamplona, Navarra, España.
(3= Departamento de Anatomía Patológica, Clínica Universidad de Navarra, Pamplona, Navarra, España.Actas Dermo-sifiliográficas 11 de MARZO de 2019
-
Identification of mutations associated with acquired resistance to sunitinib in renal cell-cancer
Elgendy M (1,2), Fusco JP (3,4), Segura V (5), Lozano MD (4,6,7), Minucci S (1,8), Echeveste JI (4,6), Gurpide A (3,4), Andueza M (3,4), Melero I (4,7,9), Sanmamed MF (3,4), Ruiz MR (3,4), Calvo A (4,10), Pascual JI (4,11), Velis JM (4,11), Miñana B (4,11), Valle RD (4,12), Pio R (4,7,13), Agorreta J (4,7,13), Abengozar M (4,6), Colecchia M (14), Brich S (14), Renne SL (14), Guruceaga E (5), Patiño-García A (4,13,15), Perez-Gracia JL (3,4,7).
(1) Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy.
(2) Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
(3) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
(4) Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
(5) IDISNA and Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Navarra, Spain.
(6) Pathology Department, Clinica Universidad de Navarra, Pamplona, Spain.
(7) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).
(8) Department of Biosciences, University of Milan, Milan, Italy.
(9) Department of Immunology, Center for Applied Medical Research (CIMA), Pamplona, Spain.
(10) Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Navarra, Spain.
(11) Department of Urology, Clinica Universidad de Navarra, Pamplona and Madrid, Spain.
(12) Department of Neurosurgery, University Clinic of Navarra, Pamplona, Spain.
(13) Program in Solid Tumors. Center for Applied Medical Research (CIMA), Pamplona, Spain.
(14) Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
(15) Department of Pediatrics and Clinical Genetics, Clinica Universidad de Navarra, Pamplona, Spain.International Journal of Cancer 08 de MARZO de 2019
-
Mannosylated nanoparticles for oral immunotherapy in a murine model of peanut allergy
Brotons-Canto A (1), Gamazo C (1), Martín-Arbella N (1), Abdulkarim M (2), Gumbleton M (2), Quincoces G (3), Peñuelas I (3), Irache JM (4).
(1) NANO-VAC Research Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008, Pamplona, Spain.
(2) School of Pharmacy and Pharmaceutical Science, Cardiff University, Cardiff, UK.
(3) Radiopharmacy Unit, Department of Nuclear Medicine, Clinica Universidad de Navarra, University of Navarra, Spain.
(4) NANO-VAC Research Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), University of Navarra, 31008, Pamplona, Spain.Journal of Pharmaceutical Sciences 05 de MARZO de 2019
tal vezLE INTERESE
¿QUÉ TECNOLOGÍA UTILIZAMOS?
La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.
NUESTROS
PROFESIONALES
Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.
POR QUÉ VENIR
A LA CLÍNICA
Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.
